

www.FirstRanker.com

www.FirstRanker.com

FINAL EXAM JUNE 2018 NATIONAL BOARD OF EXAMINATIONS

MEDICAL ONCOLOGY

PAPER-III

MEDONCO/J/18/17/III

Time: 3 hours Max. Marks:100

IMPORTANT INSTRUCTIONS

- Attempt all questions in order.
- Each question carries 10 marks.
- Read the question carefully and answer to the point neatly and legibly.
- Do not leave any blank pages between two answers.
- Indicate the question number correctly for the answer in the margin space
- Answer all the parts of a single question together.
- Start the answer to a question on a fresh page or leave adequate space between two answers.
- Draw table/diagrams/flowcharts wherever appropriate.

Write short notes on:

1.	 a) Epidemiology of gastric cancer in India. b) Risk factors for gastric cancer. c) Impact of molecular biology in the treatment of gastric cancer. 	3+3+4
2.	 a) Define concept of metronomic therapy. b) List various agents with dose/schedule which could be used for this approach. c) Plan metronomic therapy for a 50-year-old lady with epithelial ovarian cancer stage IIIC who has received 4 lines of therapy and now having progressive disease. 	2+4+4
3.	 a) Enumerate the incidence & risk factors for breast cancer associated lymphedema. b) Management of breast cancer associated lymphedema. c) How will you palliate backache in a lady with breast cancer having multiple vertebral metastases? 	3+3+4
4.	 a) Enumerate the steps of drug development process. b) What are the objectives of phase-1 Clinical trial? c) Briefly give plan with essential components of a clinical trial for study of palliative chemotherapy for advanced gall bladder cancer with jaundice. 	3+3+4
5.	 a) List the changes in the staging of head & neck cancer in the recent AJCC 8th edition. b) What are the distinct clinical features of HPV associated oropharyngeal cancers? c) Role of immunotherapy in head & neck cancer. 	3+3+4
6.	 a) Plan investigations in a newly diagnosed case of smoldering multiple myeloma in a 60-year-old male. b) How do you stage myeloma? c) Discuss choice of induction therapy in a newly diagnosed transplant eligible multiple myeloma. 	3+2+5

P.T.O.

-

FirstRanker.com

www.FirstRanker.com

FINAL EXAM JUNE 2018 NATIONAL BOARD OF EXAMINATIONS

- 7. a) Critically discuss any two chemoprevention trials in breast 3+3+4cancer. b) List various paraneoplastic syndromes associated with breast cancer. c) Indications and side effects of PARP (Polyadenosine diphosphate ribose polymerase) inhibitors. 8. Briefly mention the risk assessment of a patient with febrile 3+3+4neutropenia. What are the indications of gram positive antibiotics in the treatment of febrile neutropenia? Enumerate the indications of primary & secondary GCSF prophylaxis. 9. А 50-year-old lady with disseminated intra-abdominal 3+3+4malignancy has cachexia and is in ECOG performance status 4.
 - a) What could be the etio-pathogenesis of cachexia in this case?
 - b) Outline supportive care for this case.
 - c) Give indications, components & complications of total parenteral nutrition in this patient.
- 10. a) List investigations for a 50-year-old male suspected to have 3+3+4 chronic myeloproliferative disorder (CMPD).
 - b) What is the basis of various molecular tests done for these disorders?
 - c) Outline management for primary myelofibrosis.